AbbVie (ABBV) and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier-crossing technology to address challenging central nervous system diseases. Aliada’s lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta antibody in development for the treatment of Alzheimer’s disease. Under the terms of the agreement, AbbVie will acquire all outstanding Aliada equity for $1.4B in cash, subject to certain customary adjustments. This transaction is expected to close in 4Q2024, subject to regulatory approvals and other customary closing conditions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Options Volatility and Implied Earnings Moves This Week, October 28 – November 01, 2024
- Is ABBV a Buy, Before Earnings?
- AbbVie price target raised to $215 from $170 at Citi
- AbbVie, Gedeon Richter collaborate for discovery, development of novel targets
- Regenxbio presents positive Phase 2 data of ABBV-RGX-314 in wet AMD